Previous 10 | Next 10 |
“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27 th at 11 AM ET SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based...
Whether you're new to investing or have been doing it for a very long time, the vast majority of the stocks in your portfolio are probably in the red this year. Rising interest rates are pushing growth stocks out of favor -- but not all of them. This year, shares of the following three ...
Belite Bio ( NASDAQ: BLTE ) is off 21% in Monday trading after reporting disappointing phase 2 results on tinlarebant for adolescent Stargardt Disease, a rare eye disease characterized by fatty material build-up in the macula. While the company presented the resul...
LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time point The majority of the subjects showed stabilization of BCVA in at least one eye A trend for preventing or slowing expansion of autofluorescence continue to b...
Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...
1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 to be presented SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently un...
Belite Bio ( NASDAQ: BLTE ) said on Friday it had received approval from the National Medical Products Administration of China to begin the Phase 3 trial of its drug, LBS-008, in adolescent with a rare type of eye disease called Stargardt disease STGD1. A 2-year Phase ...
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease (STGD1) and Dry AMD patients A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STG...
Recently IPO’d Belite Bio, Inc ( NASDAQ: BLTE ) ended a four-day selloff on Monday to climb ~15% after the biopharma company announced the enrollments of its pivotal U.S. Phase 3 clinical trial for lead candidate LBS-008 in patients with eye disorder Stargardt Disea...
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing The Phase 3, Multi-center, Randomized, D ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...